47+ results for “AAV9”
Breakthrough serotype capable of crossing the blood-brain barrier systemically. Revolutionized CNS gene therapy with broad neuronal and glial transduction. FDA-approved for spinal muscular atrophy.
AAV9 variant with modified tropism profile for balanced tissue distribution with focus on muscle and cardiac tissue.
First-generation blood-brain barrier penetrating AAV variant evolved from AAV9 using CREATE methodology. Mouse strain-specific due to LY6A receptor dependence.
Rhesus macaque-derived serotype with strong liver and skeletal muscle tropism. Part of the expanded AAV toolkit from non-human primate tissue screening.
Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes
Engineering liver-detargeted AAV9 vectors for cardiac and musculoskeletal gene transfer
Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy
Infectious clones and vectors derived from adeno-associated virus (AAV) serotypes other than AAV type 2